双相障碍I型患者治疗前后微小RNA206基因表达水平变化及与对照的比较(英文)  

Changes in the level of micro RNA-206 gene expressionin patients with type Ⅰ bipolar disorder before and after treatment and comparison with a control population

作　　者：汪作为[1,2] 李则挚[1] 王凌霄 吴志国[1] 苑成梅[1] 洪武[1] 禹顺英[1] 方贻儒[1] 

机构地区：[1]上海交通大学医学院附属精神卫生中心心境障碍科,200030 [2]上海市虹口区精神卫生中心,200083

出　　处：《上海精神医学》2011年第5期272-277,共6页Shanghai Archives of Psychiatry

基　　金：provided by the National Natural Science Foundation of China (grant No. 30971047);the Department of Public Health of the Hongkou District of Shanghai (project No. 91 for 2010);虹口区重大医学科研课题[虹卫1101-02]~~

摘　　要：背景微小RNA206(MicroRNA-206,miRNA-206)可能是双相障碍的生物学标志之一,有待深入探究。目的评估双相障碍躁狂发作期外周血miRNA-206水平与患者临床状态的关系。方法采用美国精神障碍诊断与统计手册第4版轴I障碍定式临床检查,符合双相障碍I型躁狂发作期的新入院患者36例和年龄、性别匹配的健康对照者30名纳入研究。健康对照者入组时,双相障碍患者在基线、治疗后第2、4、8周末外周血淋巴细胞miRNA-206水平被检测。在检测miRNA-206水平相同时间点,采用杨氏躁狂量表(YoungMania Rating Scale,YMRS)评估双相障碍患者躁狂症状严重程度。结果在基线(Z=-0.02,P=0.988)和治疗后第2周末(Z=-0.17,P=0.864)、第4周末(Z=-0.86,P=0.392)、第8周末(Z=-1.29,P=0.197),双相障碍患者与健康对照者之间外周血miRNA-206水平差异无统计学意义。对于双相障碍患者,在4个时间点miRNA-206水平与躁狂症状严重程度之间也无统计学明显相关(统计值依次为:rs=0.13,P=0.518;rs=0.12,P=0.532;rs=-0.18,P=0.361;rs=0.02,P=0.912)。结论外周血淋巴细胞miRNA-206水平可能不是双相障碍I型或躁狂发作期治疗效果的生物学标志。由于本研究检测患者与对照者之间差异的统计效能仅22%,今后需要大样本研究(可能应用不同技术检测miRNA-206水平)进一步验证。Background： Micro RNA-206（miRNA-206） is a potential biomarker of bipolar disorder that has not yet been fully investigated. Objective： Assess the relationship between the level of miRNA-206 in peripheral blood and the clinical state of pa- tients in the manic phase of bipolar disorder. Methods： Thirty-six newly admitted patients in the manic phase of type I bipolar disorder （diagnosed using the Structured Clinical Interview for DSM IV Axis I disorders） and 30 age and gender matched healthy controls were enrolled, miRNA-206 levels in peripheral blood lymphocytes were assessed at the time of enrollment in control subjects and at baseline and at the end of the second, fourth and eighth week of treatment in the patient group. The severity of manic symptoms in the patient group was evaluated at the same time as the miRNA-206 assessments using the Young Mania Rating Scale. Results： There were no statistically significant differences in baseline miRNA-206 levels between patients and con- trols （Z=-0.02, P=0. 988） or, in the patient group, between baseline levels and those at the end of the second （Z=-0.17, P=0. 864）, fourth （ Z =-0.86, P =0.392） and eighth （Z =-1.29, P =0. 197） weeks after initiating treatment. There were also no statistically significant correlations between the miRNA-206 level and the severity of manic symptoms at any of the four time points （ rs =0.13, P = 0.518; rs =O. 12, P = 0. 532; rs =-0.18, P = 0. 361 ; and rs =0.02, P=0.912; respectively）. Conclusion： The activity of miRNA-206 in peripherally blood lymphocytes does not appear to be a biomarker of type I bipolar disorder or a biomarker for treatment efficacy during the treatment of a manic episode. But the power to detect differences between patients and controls in the study was only 22% so further research with larger samples （ possibly using different techniques to assess miRNA-206 activity） are needed to confirm these findings.

关 键 词：双相障碍 躁狂发作 微小RNA-206 淋巴细胞 基因表达 

分 类 号：R749.4[医药卫生—神经病学与精神病学]